Related Experiment Video
Updated: Sep 24, 2025
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.7K
AD and its comorbidities: An obstacle to develop a clinically efficient treatment?
1Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Revue Neurologique
|May 6, 2022
Summary
Alzheimer's disease (AD) treatments face challenges due to comorbidities often excluded from trials. Adapting clinical trials to include these conditions is crucial for developing effective AD therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Alzheimer's disease (AD) lacks treatments proven to slow progression.
- Regulatory divergence (FDA vs. EMA) on aducanumab highlights efficacy and safety concerns.
- Comorbidities are common in AD patients but often excluded from clinical trials.
Purpose of the Study:
- To discuss the impact of comorbidities on Alzheimer's disease (AD) treatment development.
- To examine evolving definitions of AD and common comorbid conditions.
- To analyze how comorbidity exclusion/inclusion affects AD trials and real-world therapeutic use.
Main Methods:
- Literature review and discussion of AD definitions and comorbidities.
- Analysis of the implications of comorbidity exclusion in clinical trials.
- Examination of the impact of comorbidities on the real-world application of AD therapeutics.
Main Results:
- Definitions of Alzheimer's disease (AD) continue to evolve.
- Several comorbidities frequently accompany or mimic AD.
- Exclusion of comorbidities from trials may limit the generalizability of treatment efficacy and safety findings.
Conclusions:
- Comorbidities significantly complicate Alzheimer's disease (AD) treatment development.
- Clinical trial designs may need adaptation to better reflect the complexities of AD patients.
- Future research should consider the impact of comorbidities for more effective AD therapeutics.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
272
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
272
01:28Drug Therapy
108
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
108
01:26Alzheimer's Disease: Overview
692
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
692
01:30Attention-Deficit/Hyperactivity Disorder
334
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
334
01:20COPD: Pathogenesis and Clinical Features
604
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
604
01:24Treatment Strategies for Psychological Disorders
293
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
293